Get Started

NVO

NYSE Novo Nordisk A/S Sponsored ADR Class B
Oct 24, 2026 · 1:33 AM ET EOD Market Closed

$39.05 ↑ +0.00 (+0.00%) Trading Up from the previous close of $39.05, $0.24 below the day’s high of $39.29

YTD change
-23.25%
vs 20-day SMA
+1.74%
vs 200-day SMA
-12.79%

Price ranges

Previous day
$39.24 $39.77
open $39.29 close $39.43
+$0.14 (+0.36%)
Today
$38.75 $39.29
open $39.15 now $39.05
-$0.10 (-0.26%)
Past week
$38.35 $39.77
from $39.22 now $39.05
-$0.17 (-0.43%)
Past month
$36.85 $39.77
from $38.62 now $39.05
+$0.43 (+1.11%)
This year
$35.12 $64.16
from $50.88 now $39.05
-$11.83 (-23.25%)

Price & Performance

+0.53 (+1.38%) / 6M

$36.18$41.70$47.23$52.75Apr 23Jul 24Oct 23

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 73.6% away from all-time highs of $148.15
  • NVO is down 23% since the beginning of the year
  • NVO is down 27% over the past 12 months
  • NVO is up 1% over the past 1 month
  • 1% of all NVO investors are betting against NVO
  • Number of investors short NVO has gone down 0% versus last month

NVO reads not so good: price sits above one of the two key moving averages, short interest is falling month over month, the 12-month move is -26.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.955119
Earnings momentum -28.8% Quarterly EPS growth
Quarterly change -28.8%

Valuation

P/E ratio 9.78
Enterprise value $189.5B
Beta 1.32

Balance sheet & scale

Income$18.3M
Revenue$51.6B
Cash$6.9B
Debt$21.4M
Income / Debt 0.85×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNYSE
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $130.7B

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,273.46 -2.54%
JNJ Johnson & Johnson $263.81 -1.42%
ABBV AbbVie, Inc. $285.64 +0.16%
MRK Merck & Co., Inc. $145.27 -1.34%
RHHBY Roche Holding Ltd Sponsored ADR $61.17 +2.60%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.